InMed Pharmaceuticals Inc.
INM- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001728328
In the last 90 days, InMed Pharmaceuticals Inc. insiders filed 7 open-market purchases and 0 sales; 20 institutions reported holding it in 13F filings for Q2 2026, worth $4.18M in total; no superinvestor holds it.
Other share classesMTRI
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 5, 2026, 12:20 AM ET
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2026 | FY2025 | FY2024 | FY2023! | FY2022 |
|---|---|---|---|---|---|
| Period end | Jun 30, 2026 | Jun 30, 2025 | Jun 30, 2024 | Jun 30, 2023 | Jun 30, 2022 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | – | – | – | – | – |
| Revenue | – | $4.94M | $4.60M | $4.14M | $1.09M |
| Cost of revenue | – | $3.24M | $3.50M | $2.42M | $545.9K |
| Gross profit | – | $1.71M | $1.10M | $1.40M | $543.5K |
| Operating expenses | $11.6M | $9.65M | $9.30M | $9.78M | $17.8M |
| Research and development | $3.03M | $2.85M | $3.77M | $3.73M | $7.28M |
| Selling, general and administrative | $6.66M | $6.56M | $5.25M | $5.85M | $6.87M |
| Operating income | – | – | – | -$7.95M | -$18.6M |
| Income tax | – | – | $7.10K | $13.1K | – |
| Net income | -$12.6M | -$8.16M | -$7.68M | -$7.95M | -$18.6M |
| EPS, basic | $-3.12 | $-8.36 | $-1.01 | $-3.25 | $-33.17 |
| EPS, diluted | $-3.12 | $-8.36 | $-1.01 | $-3.25 | $-33.17 |
| Weighted shares, basic | 4.16M | 976.0K | 7.62M | 2.45M | 560.8K |
| Weighted shares, diluted | 4.16M | 976.0K | 7.62M | 2.45M | 560.8K |
| Margins and growth | |||||
| Gross margin | – | 34.5% | 23.9% | 33.9% | 49.9% |
| Operating margin | – | – | – | -192.2% | -1707.3% |
| Net margin | – | -165.1% | -166.9% | -192.2% | -1707.3% |
| Revenue growth, year over year | – | +7.5% | +11.2% | +279.6% | – |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Period end | Jun 30, 2026 | Jun 30, 2025 | Jun 30, 2024 | Jun 30, 2023 | Jun 30, 2022 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | – | – | – | – | – |
| Cash and equivalents | – | $11.1M | $6.57M | $8.91M | $6.18M |
| Short-term investments | $39.7K | $43.4K | $43.1K | $44.4K | $44.8K |
| Accounts receivable | – | $465.1K | $352.8K | $260.4K | $88.0K |
| Inventory | – | $961.2K | $1.24M | $1.62M | $2.49M |
| Total current assets | $2.68M | $12.9M | $8.69M | $11.3M | $9.60M |
| Property, plant and equipment | $221.0K | $992.2K | $1.25M | – | $904.3K |
| Intangible assets | – | $1.62M | $1.78M | $1.95M | $2.11M |
| Total assets | $3.03M | $15.6M | $11.8M | $14.1M | $12.8M |
| Accounts payable | – | – | $41.0K | – | – |
| Total current liabilities | $1.96M | $1.84M | $1.97M | $2.00M | $3.32M |
| Total liabilities | $1.96M | $2.15M | $2.62M | $2.02M | $3.71M |
| Shareholders' equity | $1.08M | $13.4M | $9.21M | $12.1M | $9.08M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|---|
| Period end | Jun 30, 2026 | Jun 30, 2025 | Jun 30, 2024 | Jun 30, 2023 | Jun 30, 2022 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | – | – | – | – | – |
| Operating cash flow | -$8.64M | -$7.77M | -$6.99M | -$7.28M | -$15.6M |
| Capital expenditures | – | – | $9.29K | $160.0K | $39.1K |
| Free cash flow | – | – | -$7.00M | -$7.44M | -$15.6M |
| Depreciation and amortization | $205.3K | $212.8K | $219.6K | $202.2K | $185.7K |
| Stock-based compensation | $106.9K | $119.3K | $137.7K | $278.2K | $697.9K |
| Investing cash flow | – | – | -$9.29K | -$661.8K | -$673.0K |
| Financing cash flow | $94.5K | $12.3M | $4.65M | $10.7M | $15.1M |
| Net change in cash | – | – | -$2.34M | $2.74M | -$1.19M |
| Ratio | |||||
| Stock-based compensation, % of revenue | – | 2.4% | 3.0% | 6.7% | 64.1% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Oct 30, 2026 | 5.49M | +95.9% | SEC |
| Sep 2, 2026 | 5.49M | +130.4% | SEC |
| May 4, 2026 | 3.31M | +174.5% | SEC |
| Feb 9, 2026 | 2.92M | +141.8% | SEC |
| Oct 31, 2025 | 2.80M | +290.5% | SEC |
| Sep 17, 2025 | 2.38M | −82.1% | SEC |
| May 9, 2025 | 1.21M | – | SEC |
| Feb 7, 2025 | 1.21M | −80.1% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
- A column marked ! failed an accounting identity (gross profit = revenue − cost of revenue, or assets = liabilities + equity, within 1%). Its numbers are shown as filed.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.